Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 103

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Colitis ulcerative

Not recruiting

Study on the Effects of Tamuzimod in Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tamuzimod Acetate
  • Sponsor:Oppilan Pharma Limited

Hereditary angioedema

Not recruiting

Study on the Safety and Effects of Berotralstat for Children Aged 2 to 12 with Hereditary Angioedema (HAE)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Berotralstat
  • Sponsor:Biocryst Pharmaceuticals Inc.

Study on the Effects of Sonelokimab for Patients with Moderate-to-Severe Palmoplantar Pustulosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Asthma

Not recruiting

Long-term safety study of dexpramipexole tablets in patients with severe eosinophilic asthma who completed EXHALE-2 or EXHALE-3 trials

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Evaluation of fenofibrate treatment on beta cell function in children and adolescents newly diagnosed with type 1 diabetes

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fenofibrate Micronised
  • Sponsor:Medical University Of Warsaw

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Graves' disease

Not recruiting

Study on the Effects of Batoclimab for Patients with Graves' Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

HIV infection

Not recruiting

Study of Injectable Cabotegravir Compared to Oral Emtricitabine/Tenofovir for HIV Prevention in Men Who Have Sex with Men

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Inserm

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Study on the Effectiveness and Safety of Danicopan for Adults with Chronic Spontaneous Urticaria Resistant to H1-Antihistamines

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.